Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes.  Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process. Coupling … Continue reading →

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key … Continue reading →

POAI announced that total stockholders’ equity increased by nearly $33 million to $35.5 million Financial report notes net proceeds of $35.6 million from private placement, direct offering, warrant exercises Company subsidiaries reached several milestone achievements throughout the quarter. Predictive Oncology … Continue reading →

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently expanded its board of directors with the appointment of Dr. Christina Jenkins. Dr. Jenkins holds capital markets expertise coupled with … Continue reading →

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and … Continue reading →

POAI appoints strategic advisor, venture investor Dr. Christina Jenkins to board of directors Dr. Jenkins’ experience spans work in capital markets, clinical medicine, public healthcare systems  Other roles include current Board Director for Independence Health Group, Venture Partner at Phoenix … Continue reading →

Bell2Bell podcast features company CEO, CFO, CTO of Helomics subsidiary POAI is “in probably the best situation we’ve been in since the existence of the company,” reports CFO Company anticipates revenue from its unique PeDAL platform Three Predictive Oncology (NASDAQ: … Continue reading →

Predictive Oncology’s (NASDAQ: POAI) subsidiary company, Helomics, was recently featured on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of industries. The company’s Chief Technical Officer, Mark Collins, PhD, … Continue reading →

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication … Continue reading →